← Leaderboards
Daping Fan
Medical University Of South Carolina
$7,089,971
Attributed
$8,714,362
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $961K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,714,362 · 11
By mechanism
R01$3,554,339 · 2
P01$1,378,159 · 1
R21$1,042,063 · 3
P20$922,002 · 2
UT1$918,358 · 1
R41$899,441 · 2
Top collaborators
- Elizabeth Angela Murphy6 shared
- Wayne E Carver2 shared
- Peisheng Xu1 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Fred Stephen Sarfo$4,523,537
- Steven A. Rosenzweig$3,554,090
- Hongkuan Fan$6,948,900
Others in their field
Top investigators on “Macrophage”
- Craig B Thompson · Sloan-Kettering Inst Can Research$41,669,179
- Howard Eliot Gendelman · Children'S Memorial Hospital (Chicago)$41,668,744
- Selwyn M Vickers · University Of Alabama At Birmingham$40,969,055
- Alan A Aderem · University Of Washington$38,969,733
- Alan Richard Tall · Columbia University Health Sciences$38,053,695
- John S Condeelis · Yeshiva University$33,855,255
Research focus
MacrophageMediatingChinese HerbsInflammatory ResponseChronicAttenuatedCellsLigandsMolecularSignal TransductionMouse ModelInflammatoryLipidsAnti-Inflammatory AgentsInflammationToll-Like ReceptorsMonocyteBaseEventPlantsTissuesAnti-InflammatoryFeedingPathogen
Grant awards (30)
Activating TFEB to enhance the efficacy of immunotherapy for triple negative breast cancer$400,000
R41 · FY2025 · CA · contact PI
Develop a novel strategy to deliver N-acetylcysteine for AD treatment$499,441
R41 · FY2024 · AG
Developing natural compound emodin as a therapy for alcoholic cardiomyopathy$461,518
UT1 · FY2024 · AA
Developing natural compound emodin as a therapy for alcoholic cardiomyopathy$456,840
UT1 · FY2023 · AA
Emodin as a chemopreventive agent for breast cancer$324,810
R01 · FY2022 · CA · contact PI
Emodin as a chemopreventive agent for breast cancer$48,051
R01 · FY2022 · CA · contact PI
Emodin as a chemopreventive agent for breast cancer$400,859
R01 · FY2021 · CA · contact PI
Emodin as a chemopreventive agent for breast cancer$355,830
R01 · FY2020 · CA · contact PI
Emodin as a chemopreventive agent for breast cancer$344,939
R01 · FY2019 · CA · contact PI
Emodin as a chemopreventive agent for breast cancer$356,494
R01 · FY2018 · CA · contact PI
Impact of macrophage PCSK9 on breast cancer$133,500
R21 · FY2018 · CA · contact PI
Sparstolonin B as a TLR antagonist in suppression of liver inflammation through e$351,422
P01 · FY2017 · AT · contact PI
Sparstolonin B as an anti-atherogenic agent$345,396
R01 · FY2017 · HL · contact PI
Impact of macrophage PCSK9 on breast cancer$160,200
R21 · FY2017 · CA · contact PI
Sparstolonin B as a TLR antagonist in suppression of liver inflammation through e$354,136
P01 · FY2016 · AT · contact PI
Sparstolonin B as an anti-atherogenic agent$345,314
R01 · FY2016 · HL · contact PI
A new Chinese herb-derived selective Toll-like receptor antagonist (Project 1)$205,500
P20 · FY2016 · GM · contact PI
Sparstolonin B as an anti-atherogenic agent$340,057
R01 · FY2015 · HL · contact PI
Sparstolonin B as a TLR antagonist in suppression of liver inflammation through e$330,537
P01 · FY2015 · AT · contact PI
A new Chinese herb-derived selective Toll-like receptor antagonist (Project 1)$205,500
P20 · FY2015 · GM · contact PI
Sparstolonin B as a TLR antagonist in suppression of liver inflammation through e$342,064
P01 · FY2014 · AT · contact PI
Sparstolonin B as an anti-atherogenic agent$338,254
R01 · FY2014 · HL · contact PI
A new Chinese herb-derived selective Toll-like receptor antagonist (Project 1)$205,500
P20 · FY2014 · GM · contact PI
Sparstolonin B as an anti-atherogenic agent$354,335
R01 · FY2013 · HL · contact PI
SsnB, a Chinese herb-derived selective TLR antagonist$166,113
R21 · FY2013 · AT · contact PI
SsnB, a Chinese herb-derived selective TLR antagonist$205,500
R21 · FY2012 · AT · contact PI
A new Chinese herb-derived selective Toll-like receptor antagonist (Project 1)$205,500
P20 · FY2012 · GM · contact PI
Monocyte microRNA155 and atherosclerosis$171,250
R21 · FY2012 · HL · contact PI
Monocyte microRNA155 and atherosclerosis$205,500
R21 · FY2011 · HL · contact PI
ROLE OF MICRORNA-155 IN MACROPHAGE FUNCTION AND ATHEROSCLEROSIS$100,002
P20 · FY2010 · RR · contact PI